Autism Spectrum Disorder is characterized by reduced spatial autocorrelation of the excitation/inhibition ratio.

Valentina Francesca Cudia[1], Chiara Davico[1*], Martina Vacchetti[2], Samuela Morano[2], Marta Giacobbi[2], Carlotta Canavese[2], Barbara Svevi[2], Federica Ricci[1], Federico Amianto[3], Benedetto Vitiello[1,4], Andrea Martinuzzi[1], Argyris Stringaris[5], Daniele Marcotulli[1*]

1. Department of Sciences of Public Health and Paediatrics, University of Turin, Italy
2. Department of Child Care, Regina Margherita Hospital, Turin, Italy
3. Department of Neuroscience, University of Turin, Italy
4. Department of Mental Health, School of Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
5. Divisions of Psychiatry and Psychology and Language Science, University College London

* Corresponding authors: chiara.davico@unito.it; daniele.marcotulli@unito.it

Abstract

Despite two decades of intensive investigation, the neurobiological underpinnings of autism spectrum disorder (ASD) defining symptoms remain elusive in large part because ASD represents a highly heterogeneous set of phenotypes, with wide-ranging genetic, neural and behavioural profiles that likely arise from multiple, partially overlapping mechanisms. Among various proposed mechanisms, the "excitation/inhibition (E/I) imbalance hypothesis" has been extensively researched, with substantial although sometimes conflicting evidence. Animal studies show that localised alterations in cortical E/I balance can disrupt network dynamics and reduce long-range connectivity, potentially explaining the weak central coherence that may be observed in ASD. However, neither the E/I imbalance hypothesis nor the weak central coherence hypothesis has provided a fully coherent explanation of ASD's neurobiology or proved useful in identifying reliable biomarkers.

Here, we present a novel integrated hypothesis that unifies these theories, proposing that it is not the global average E/I ratio but rather its spatial heterogeneity across brain regions that may be altered in ASD and that disrupts the integration of brain network activity. To test this hypothesis, in a series of pre-registered analyses, we assessed EEG-derived E/I spatial autocorrelation in children with ASD (n = 248) and in neurotypical controls (n = 105). Our findings indicate significantly lower spatial autocorrelation in children with ASD, suggesting increased E/I variability across regions (*estimate:* -0.51, 95% CI: -0.69 – -0.33), both in wakefulness (total wakefulness EEGs n = 234; *estimate* -0.36, 95% CI: -0.63 – -0.081) and sleep EEG (total sleep EEGs n = 304; *estimate* -0.49, 95% CI: -0.75 – -0.23).
Importantly, we validated these results in a large external dataset (ASD n = 230, NT n = 167; *estimate*: - 0.22, 95% CI -0.33 – -0.02) compiled from the National Institute of Mental Health Data Archive (NDA), reinforcing the robustness of our findings.

Moreover, when exploring diagnostic accuracy, EEG-based E/I spatial autocorrelation along with sex differentiated ASD from neurotypical status with fair performance (ROC AUC: 0.725, sensitivity: 0.89, specificity: 0.67), highlighting its potential for optimization as a cost-effective screening tool. Overall, these results illuminate a possible

neurobiological signature of ASD and suggest that EEG measures of E/I spatial heterogeneity may serve as a viable biomarker for the condition.

Introduction

Despite decades of intensive investigation, the neurobiological basis of autism spectrum disorder (ASD) remains elusive[1,2], hindering efforts to identify reliable biomarkers, perhaps with the exception of eye-tracking patterns[3].

Among the hypotheses on the neurobiological determinants of ASD, the excitation/inhibition (E/I) imbalance[4], the "weak central coherence theory", and the abnormal brain connectivity have received substantial research support[5–7]. Yet, when considered independently, neither theory provided a fully coherent explanation of the neurobiology of ASD, nor proved useful in identifying reliable biomarkers (with minor exceptions, such as EEG spectral coherence, which have not entered clinical practice)[8]. Animal research shows that cortical patches with altered E/I balance can result in abnormal network dynamics and diminished long-range connectivity[9], suggesting a mechanistic link between E/I imbalance and abnormal brain connectivity. Here, we present a novel integrated hypothesis that unifies these theories to shed new light on the condition's neurobiological basis, and we include preliminary evidence supporting the use of this combined measure as a promising indicator of ASD in early development. By uniting these perspectives, we offer a more coherent explanation of ASD than either theory can provide in isolation.

The E/I hypothesis suggests that some forms of ASD result from an excessively high level of excitatory drive (mainly sustained by glutamatergic neurotransmission) or disproportionately weak inhibition (mainly resulting from GABAergic neurons) in specific brain regions, particularly those involved in language and social behaviour, although regions with reduced E/I ratios have also been reported in ASD[10].

Animal models of ASD demonstrate alterations in E/I balance in several regions, including the prefrontal cortex, somatosensory cortex, hippocampus, and cerebellum[11–14]. These changes demonstrated to be sufficient to induce behaviours considered analogous of human ASD symptoms. This evidence enhances our understanding of ASD but also highlights its complexity and heterogeneity[11]. Similarly, in humans, altered E/I balance has been observed in various regions, such as the

prefrontal cortex, striatum, visual cortex, and temporal lobe[15–18]. These alterations are believed to contribute to core ASD symptoms, though findings remain highly heterogeneous due to phenotypic differences, genetic variability, and environmental factors. Notably, children with ASD exhibit pronounced variability in the brain-averaged E/I ratio, showing more extreme deviations from the balance point in both directions. This may contribute to the clinical and neurobiological heterogeneity observed in ASD[19]. The mounting evidence for E/I imbalance in ASD has led to clinical trials of drugs targeting glutamatergic and GABAergic neurotransmission[20,21]. Additionally, transcranial magnetic stimulation (TMS) is being investigated for its potential to modulate cortical excitability and alleviate ASD-like symptoms[22].

The “weak central coherence” theory of ASD involves deficits in brain integration circuits, consistent with hyper-detailed processing but lacking efficient hierarchical organization[23]. EEG studies have suggested that the neural underpinnings of this phenomenon may be a characteristic pattern of local hyperconnectivity and global hypoconnectivity, indicating an abnormal neural network organization in ASD[8,24]. Specifically, there is evidence of increased coherence in short-range connections (particularly in frontal and temporal regions) and reduced synchronization in long-range alpha-band connectivity (8–10 Hz), which is crucial for inter-regional communication[25].

Although substantial theoretical support and some empirical findings suggest that E/I imbalance and altered brain connectivity play important roles in ASD, current human evidence remains limited and inconsistent[1]. Moreover, there has been little integration between studies focusing on E/I imbalance and those investigating network connectivity. Indeed, previous research on ASD has typically evaluated either the average E/I ratio across broad or highly specific cortical regions or global connectivity. However, both approaches can dismiss regional differences in E/I. An overall average E/I metric across the brain may present with near-normal mean E/I balance that masks patch-like disruptions of excitability states that impair network integration.

Building on these findings and addressing the current knowledge gap, the present study tested whether it is not the overall average brain E/I that is altered in ASD, but rather the variability of E/I across different regions, and whether this increased heterogeneity could serve as a biomarker for ASD.

Specifically, we hypothesise that in ASD, cortical "patches" show either hyperexcitability or strong inhibition, so that the variability of E/I from one patch to the next can be significantly higher. These patches could arise for multiple reasons, such as region-specific developmental anomalies or genetic determinants. These focal E/I disruptions may reinforce local connectivity but compromise the synchronized network activity required for global integration. Phenotypically, this may manifest as hyper-detailed perception in specific domains and greater difficulty integrating higher-level contextual information—aligning with the concept of weak central coherence[7,23].

To quantify this heterogeneity of excitability states across the cortical surface, we employed spatial autocorrelation because it captures how E/I values at one location correlate with values at other locations, in relation to the distance between electrodes. Therefore, lower spatial autocorrelation of E/I would indicate the presence of patches with atypical excitability that do not integrate with surrounding areas: if local E/I states are unusually distinct from each other, the integration between those adjacent local circuits will be disrupted as is suggested by local–global connectivity differences in ASD.

Furthermore, the E/I balance significantly differs during sleep compared to wakefulness[26,27], and sleep offers a relatively stable brain state to examine circuit properties without the interference of continuous sensory input and active cognition, which may be altered in ASD.

Given the crucial contribution of sleep to neurodevelopment and the frequent occurrence of sleep disturbances in ASD[1], we examined spatial heterogeneity of E/I across the first years of life, also assessing differences between sleep and wakefulness.

Given these gaps and theoretical considerations, we designed the present study to test three pre-registered hypotheses, focusing on whether spatial variability in E/I contributes to ASD neurobiology:

H1: The spatial autocorrelation of E/I (the EEG-derived E/I being measured using the method described by Donoghue and colleagues[28]) is lower in ASD patients compared to NT individuals.

H2: To determine whether spatial autocorrelation operates as a dichotomous feature or as a determinant of ASD severity, we tested whether greater spatial heterogeneity (i.e., lower spatial autocorrelation) of E/I is associated with increased severity of ASD symptoms in patients.

H3: To confirm that reduced E/I spatial autocorrelation is a stable, trait-like characteristic of ASD rather than a state-dependent phenomenon, we tested whether the spatial heterogeneity of E/I balance persists across both wakefulness and sleep.

Results

Sample description

A total n=248 subjects diagnosed with ASD, who had an EEG as part of their routine diagnostic workup, were enrolled. Descriptive information is provided in (**Table 1)**. The majority were male (79%) and the mean age at the time of the EEG was 66.1 months (range: 20 to 202 months). Autism symptoms severity, based on DSM-5 criteria and assessed by trained child and adolescent neuropsychiatrists, was distributed as follows: 31 patients (12.5%) were classified with Level 1 severity, 64 patients (25.8%) with Level 2 severity, and 58 patients (23.4%) with Level 3 severity. Additionally, 35% of the sample presented with one or more comorbidities, the most common being intellectual disability of varying degree.

A separate control group of 105 neurotypical (NT) individuals was selected from Emergency Room (ER) admissions (**Table 1**). Of this group, 51 were males (48.6%). The mean age at admission was 101.49 months (range: 15 to 215 months). The most frequent reasons for admission included loss of consciousness (38%), non-epileptic paroxysmal movements (26.7%) and headache (23.8%). Associated neurodevelopmental disorders (such as intellectual disability) were considered exclusion criteria.

According to clinical and technical considerations, EEGs were recorded during wakefulness, sleep or both states. Expert paediatric neurologists reported the presence of EEG anomalies in 61.7% of the EEGs in ASD patients (mainly epileptiform discharges). In the NT group, abnormalities were identified in 25.2% of the EEGs (**Supplementary Table 1**).

H1: The spatial heterogeneity of E/I balance is greater in ASD individuals compared to NT individuals.

To test the hypothesis that greater spatial heterogeneity in the E/I balance is associated with ASD symptoms, we used Moran's I to quantify spatial heterogeneity and the aperiodic exponent as a validated electrophysiological proxy for E/I. Moran's I is a measure of spatial autocorrelation centred on zero, such that positive values indicate clustering and negative values indicate dispersion. The aperiodic exponent has been shown to reliably reflect E/I balance[29] and exhibits good test–retest reliability[30].

The estimate (beta) for ASD was -0.51 (95% CI: -0.69 – -0.33), indicating a significant difference in Moran's I between ASD patients and NT individuals. The negative estimate suggests that ASD patients have a lower spatial autocorrelation compared to NT individuals, reflecting greater spatial heterogeneity of the E/I supporting the hypothesis. Age and sex were not associated with E/I Moran's I. The model explained a moderate amount of variance (42.6%), underscoring the robustness of the findings.

In accordance with our hypothesis, the average E/I was not different in the ASD group compared with the NT (ASD EEGs n = 343; NT EEGs n = 197; estimate: -0.08; 95% CI: -0.25 – 0.09) (**Supplementary Table 2a**). However, when analysing separately the average E/I in the two arousal states, we found a state-dependent lower E/I in wakefulness in children with ASD (ASD EEGs n = 213; NT EEGs n = 94; estimate: -0.33; CI: -0.62 – -0.05), but not during sleep (ASD EEGs n = 130; NT EEGs n = 105; estimate: 0.19; 95% CI: -0.08 – 0.45) (**Supplementary Table 2b e 2c**).

Additionally, given the non-negligible differences in mean age and percentage of males between the two groups (**Table 1**), we used an optimal pair matching algorithm

to re-sample from the original samples and thereby create two groups matched by age and sex. We then weighted the linear regressions using these matching weights. Results in the matched populations confirmed the lower spatial autocorrelation in ASD (ASD EEGs n = 197; NT EEGs n = 197; estimate: -0.44; 95% CI: -0.63 – -0.24) (**Supplementary Table 3**).

As a sensitivity analysis to assess whether our results were influenced by the chosen measure of E/I, we used beta power as a surrogate proxy for E/I. We then calculated Moran's I across electrodes, following the same approach as for the 1/f-like exponent described below. The results were consistent with our hypothesis of greater spatial heterogeneity of E/I in ASD (ASD EEGs n = 343; NT EEGs n = 197; estimate: -0.40; 95%, CI: -0.63 – -0.17) (**Supplementary Table 4**).

Additionally, as a further sensitivity analysis, we excluded participants who received dimetindene maleate (ASD EEGs n = 113 of the total n = 343) or melatonin (ASD EEGs n = 211 of 343; NT EEGs n = 86 of 197) as sleep aids during EEG recordings, to control for potential confounding effects of melatonin or the antihistaminergic agent on E/I autocorrelation[31,32]. Even after this adjustment, the results continued to support our hypothesis of heightened E/I heterogeneity in the ASD group (ASD EEGs n = 230; NT EEGs n = 197; estimate -0.54, 95% CI: -0.74 – -0.34 after excluding dimetindene-treated individuals; estimate -0.34, 95% CI: -0.63– -0.04 after excluding patients who received melatonin, ASD EEGs n = 132; NT EEGs n = 111). (**Supplementary Table 5a e 5b**)

We then verified that the results were not influenced by the higher prevalence of intellectual disability or epileptiform discharges in the ASD group. When excluding patients with intellectual disability and global developmental delay, the analysis revealed lower Moran's I in the ASD group (ASD EEGs n = 127; NT EEGs n = 147; estimate: -0.45, 95% CI -0.69 – -0.21) lending further support to our hypothesis (**Supplementary Table 6**). Similarly, when excluding EEGs with anomalies lower spatial E/I autocorrelation was observed in the ASD group (ASD EEGs n = 125; NT EEGs n = 197; estimate: -0.42, 95% CI -0.65 – -0.18) (**Supplementary Table 7**)

Finally, we validated our findings using a publicly available external dataset[33] (https://github.com/adede1988/SheffieldAutismBiomarkers/tree/main) compiled from several large NDA studies (https://nda.nih.gov/edit_collection.html?id=2022). We employed the exponent of the aperiodic component normalized by the power distribution as our E/I measure to control for inter-dataset differences in overall signal amplitude. Among the three age brackets considered by Dede and colleagues, we focused on the youngest group because it was the most represented also in our sample and because our results and prior work[34] suggests that regional differences of E/I may vary with age. Also in this external sample, we found that spatial autocorrelation of E/I was lower in the ASD population, further validating our hypothesis (**Supplementary Table 8**) (ASD n = 230, NT n = 167; estimate: - 0.22, 95% CI -0.33 – -0.02). The same was not true in the older age groups (estimate: 0.05; 95% CI: -0.08 – 0.17), suggesting that the reduced E/I autocorrelation may be a feature that characterizes ASD during the first years of life.

H2: Greater spatial heterogeneity of E/I balance is not associated with increased severity of ASD symptoms in patients.

Moran's I was also used to investigate whether the spatial heterogeneity of E/I balance in ASD patients is associated with greater symptom's severity (based on DSM-5 criteria) (**Table 3**). The key predictor, Moran's I, had an estimate of 0.05 (ASD EEGs n = 209; 95% CI: -0.10 – 0.20), indicating no evidence that spatial heterogeneity in the E/I balance contributes to ASD symptom severity as indicated by the DSM-5 levels.

H3: Spatial heterogeneity of E/I balance persists both in wake and sleep.

Given the importance of sleep in neurodevelopment and that reduced E/I spatial autocorrelation is hypothesized to be a stable, *'trait-like'* feature of ASD rather than state-dependent, the spatial heterogeneity of E/I balance was analysed across two EEG recording conditions: wakefulness (resting with eyes closed) and sleep.

In the wake condition, ASD diagnosis had a negative association with spatial heterogeneity, with an estimate of -0.36 (ASD EEGs n = 130; NT EEGs n = 105; 95% CI: -0.63 – -0.081, **Table 4**). This indicates that ASD is significantly associated with variations in the E/I spatial autocorrelation during wakefulness. Neither age nor sex

showed any association in this condition. During sleep, the same association with ASD was observed, with an estimate of -0.49 (ASD EEGs n = 213; NT EEGs n = 94; 95% CI: -0.75 – -0.23, **Table 4**). Additionally, age had a small but significant association with E/I spatial autocorrelation in sleep, while sex did not. These findings indicate that the higher spatial heterogeneity of E/I ratio in ASD persists across both wakefulness and sleep.

After age and sex-matching, the results still confirmed a lower E/I spatial autocorrelation in children with ASD both during wakefulness (ASD EEGs n = 104; NT EEGs n = 104; estimates: -0.30, 95% CI: -0.58 – -0.02) and during sleep (ASD EEGs n = 93; NT EEGs n = 93; estimate: -0.46, 95% CI: -0.74 – -0.17) (**Supplementary Table 9a and 9b**).

Distribution of E/I ratio across electrodes.

We next examined whether specific brain regions or electrode sites were primarily responsible for the reduced spatial autocorrelation observed in children with ASD. To do this, we conducted a univariate mass analysis on the E/I metric. The analysis revealed that during wakefulness, the frontal-polar, central, and temporal regions exhibited elevated E/I ratios (**Supplementary Table 10a**). In contrast, the sleep EEG data showed that frontal, parietal and occipital regions demonstrated altered E/I dynamics (**Supplementary Table 10b**), suggesting that these differences may be state-dependent.

E/I autocorrelation as a biomarker of ASD.

Considering the described findings in the pre-registered analyses, we analysed, in a non-pre-registered exploratory evaluation, the performance of the E/I spatial autocorrelation in distinguishing individuals with ASD from NT peers. Because recent evidence suggests sex differences[34] in spatial E/I autocorrelation and the different prevalence of ASD between sex, we accounted for sex along with spatial heterogeneity of E/I in a logistic regression model. Thus, we measured the AUC of the ROC curve of this model. To this end, we derived two sex-matched populations using the *MatchIt* algorithm[35] for calculating the diagnostic performances of our model.

Results revealed an AUC of 0.725 (**Figure 1**) (sensitivity 0.84, specificity 0.52). When cross-validating this result with a leave-one-out approach we obtained a similar AUC of 0.71.

Discussion

Our findings demonstrate that increased spatial heterogeneity in the E/I ratio characterizes the EEG of children with a diagnosis of ASD.

These results align with previous studies reporting altered regional E/I balance in ASD[36], particularly in the prefrontal cortex and sensory regions[37,38]. While prior studies have often focused on isolated regions of the brain or average brain dynamics, our results emphasize the importance of considering spatial heterogeneity across multiple regions, thereby providing a more comprehensive understanding of E/I imbalances in ASD. In line with this view, a seminal study[39] identified patch-like disruptions in cortical architecture in children with ASD, which may represent focal areas of altered E/I balance.

Our sample consisted primarily of young children, many of whom were of very young age. During the early phases of brain development, neural activity and fine-tuned excitability help refine neural connections, when balance is significantly perturbed as it would results from locally disrupted E/I balance, this could lead to the altered connectivity and atypical neural processing often reported in ASD. Such disruptions might begin as local changes in cortical excitability and extend to network-level impairments, potentially leading to the behavioural and cognitive characteristics observed in ASD. This interpretation is also strengthened by the findings in the NDA dataset, where a reduced spatial autocorrelation was evidenced in the youngest group but not at older ages.

The finding of a slight change in the average E/I during wakefulness, suggests that the increased mental activity and alertness during wakefulness may slightly alter overall brain excitability, leading to the small observed change in average E/I, which is not seen during less active states like sleep. However, the observed difference between ASD and NT appears to be milder than the evidenced increase in spatial variability.

This suggests that the pattern of E/I distribution across brain regions is more important for brain network function than the overall average E/I level.

Our findings also reveal that this heterogeneity is evident in both wakefulness and sleep, highlighting its potential as a stable, state-independent, neural marker of ASD. Few prior studies have examined state-dependent variations in E/I balance, yet this area of research may be crucial for understanding the stability and reliability of these markers[26].

The elevated E/I ratio in the frontal, central, and temporal regions suggests these areas may be critical to the neurobiology of ASD. Since the frontal cortex supports executive functions and social cognition, the central regions has a major role in sensorimotor integration, and the temporal areas in language and auditory processing—this heightened E/I may underlie core behavioural and cognitive symptoms of ASD, consistent with previous research[15,40]. The altered E/I ratios in wakefulness EEG indicates that the E/I difference in ASD compared to NT is not uniform across brain states.

Interestingly, the spatial heterogeneity of the E/I ratio was not associated with DSM-V symptom severity, suggesting that this feature may operate with a dichotomous behaviour rather than reflecting symptom severity gradations. Alternatively, it could indicate that the DSM-based severity measure lacks the precision needed to capture the specific neurobiological disruptions that E/I heterogeneity reflects. Moreover, the absence of a correlation with symptom severity does not exclude the possibility that this marker is relevant across a wider spectrum of neurodevelopmental conditions where E/I is known to play a major role. Therefore, future studies with more refined clinical characterization will be essential. Similarly, other genetic and/or phenotypic characteristics of ASD may be associated with altered E/I spatial heterogeneity. Importantly, this finding does not diminish the potential of using E/I spatial distribution to cluster patients with ASD into clinical subtypes that may respond differently to therapeutic interventions[41]. Besides, identifying regions with altered E/I for each individual may provide the basis for targeted, personalized treatments using neuromodulation (e.g. TMS).

The fair performance of the E/I Moran's I in distinguishing between ASD and NT suggests that this measure could be optimized as a cost-effective and straightforward tool for early ASD screening.

Study limitations

When interpreting the findings of this study, several limitations must be considered.

First, this study was retrospective and EEG data were collected in a clinical setting rather than under standardized research conditions. Consequently, there is variability in the data due to differences in the clinical circumstances of each recording. Additionally, children with ASD may experience heightened stress during EEG testing, possibly due to increased tactile sensitivity and sensory processing challenges, which could have impacted the consistency and quality of the recordings.

ASD diagnoses and assessments were performed at multiple centres and by different clinicians. This introduces heterogeneity in diagnostic criteria and evaluation methods, which could affect the comparability of the patient data. Differences in diagnostic practices across institutions may have led to variations in the classification or severity scoring of ASD in the study cohort. While these factors may add noise to the dataset, without undermining the hypothesis of spatial E/I imbalance in ASD, , the study's real-world clinical setting can also be viewed as a strength, as it reflects typical clinical practice and likely enhances the reproducibility of the findings in similar environments.

Although the two samples differed markedly in both male percentage and mean age, sensitivity analyses with matched samples were performed to reduce the impact of these discrepancies. Nonetheless, future studies should address sample matching more rigorously (e.g., via randomization).

Furthermore, while efforts were also made to appropriately match the sample for evaluating the diagnostic performance of the E/I spatial autocorrelation, the unequal size in the two groups may have led to overestimation of its diagnostic performance that should be evaluated in future work.

Overall, our sample reflects a typical paediatric ASD population. However, it may include a disproportionately high number of children with intellectual disability, and it may underrepresent milder ASD cases because those children are less likely to undergo comprehensive diagnostic evaluations that include EEG. Importantly, external validation with the dataset compiled by Dede et al. which include a smaller percentage of severe ASD and intellectual disability cases helps mitigate concerns about potential referral biases.

Lastly, the control group was drawn from children admitted to the emergency room rather than from the general population. This selection process could have introduced a bias, as children admitted to the ER might not fully represent healthy neurotypical controls. For instance, ER admissions might include children with transient neurological complaints or other stress-related factors that could affect their EEG profiles.

While efforts were made to mitigate these issues through data preprocessing and quality control, a prospective study could address these challenges by standardizing clinical assessment and data collection and by recruiting a well-matched control group from the general population under standardized conditions.

Conclusions

This study provides evidence that spatial autocorrelation in the E/I may offer a novel perspective on the neurobiology of ASD and could serve as a promising neural marker for the condition. Our findings highlight that E/I imbalances are not uniformly distributed across the brain but are region-specific, supporting the importance of studying the impact of regional brain alterations on network dynamics in ASD. Moreover, this heterogeneity was evident across both wakefulness and sleep, underscoring its potential as a stable index for ASD.

The regional and stable differences in E/I balance may inform targeted interventions. For example, neuromodulatory treatments (e.g. TMS) might be refined to specifically address the dysregulation in the identified key areas.

Spatial heterogeneity in the E/I ratio holds promise as a basis for early screening in ASD. Its potential to guide personalized therapeutic strategies could significantly enhance outcomes for individuals with ASD. Future research should aim to expand on these findings by integrating advanced electrophysiological techniques, longitudinal designs, and larger populations to further elucidate the role of E/I balance in ASD and other neurodevelopmental disorders.

Materials and methods

Participants

This retrospective study was based on clinical data collected from patients who attended the neurological Day Hospital at the Regina Margherita Children's Hospital, University of Turin, between January 30, 2018, and May 29, 2024.

Inclusion criteria for the case group were the following:

- Children (age<18 years) with a previous diagnosis of autism spectrum disorder made by an expert child and adolescent neuropsychiatrist, using standard diagnostic instruments.
- Written informed consent for research purposes signed by parents or legal guardians.
- An EEG performed on the date of the admission.

The control group for this study was derived from hospital data of patients (children under 18 years of age) admitted to the emergency department during the same period. These patients were referred for neuropsychiatric evaluation due to symptoms such as headache, loss of consciousness, alteration of consciousness or paroxysmal movements. Exclusion criteria applied to the control group included a diagnosis of developmental disorder and epilepsy or seizure.

248 patients were recruited in the case group and 105 patients were recruited in the control group.

All the procedures were approved by the local ethics committee and parents or legal tutors of ASD patients gave informed consent. Control EEGs were collected anonymously.

Results were then validated in a publicly available database (Dede at al., 2025).

Measures and EEG Recordings

Demographic and clinical data were collected through electronic medical records. For the case group, the collected data included: age at the admission, sex, comorbidities, symptom severity based on DSM-5 criteria (level 1, 2 or 3), and EEG description. For the control group, the collected data included: age, reason of admission, sex, anamnestic data, comorbidities, EEG description.

Children in the case group underwent baseline standard EEG recording as part of a comprehensive diagnostic protocol. For children in the control group, EEG recordings were performed during their diagnostic evaluation for reasons other than ASD, epilepsy and encephalitis/encephalopathies. (see Supplementary Methods for further information on EEG recordings).

Trained paediatric neurologists evaluated the EEGs for presence and localization of epileptiform discharges.

EEG Data Analysis

Study registration, open science and code availability.

The three main hypotheses and their analyses were registered on the Open Science Framework before analysing the data (https://osf.io/6dhkx/). Python and R codes for data cleaning and analysis are available in GitHub at https://github.com/danielemarcotulli/ASD_EI_ANALYSES .

Extraction of E/I measure

To derive E/I from EEG segments, we employed the spectral parameterization technique described by Donoghue and colleagues[28]. We focused on exponent of the aperiodic component, a well characterized electrophysiological proxy for the E/I balance that can be extracted from each EEG trace derived from each skull electrode.

Moran's I extraction

To quantify the spatial heterogeneity of E/I for each patient, we computed Moran's I across EEG electrodes separately for sleep and wakefulness recordings. Spatial weights were derived by calculating pairwise Euclidean distances between electrodes and then taking their inverse, with diagonal values set to zero. Using this spatial structure, Moran's I was computed under a permutation framework (999 permutations) to generate an empirical reference distribution, from which Moran's I and its variance were derived. More negative Moran's I values indicate higher spatial heterogeneity (lower spatial autocorrelation) in EEG signals.

Beta Power

Spectral power in the beta frequency range (12–33 Hz) was computed using Welch's method. (see Supplementary Methods).

Statistical Analysis

For models evaluating both sleep and wakefulness EEG we employed linear mixed models with random intercepts for individuals and EEG state. For models evaluating the association between EEG features and ASD we used linear regression. All estimates and their confidence intervals were standardized. When analysing matched populations, we used the matching weights as regression weights in the regression model.

Univariate mass analysis was used to assess whether any electrode E/I was differentially heightened or lower in ASD individuals.

All regression models for sleep and wakefulness were adjusted for the patient's age and biological sex.

To evaluate the performance of the E/I spatial autocorrelation in discriminating between ASD and NT, a logistic regression model was utilized. The binary outcome variable was the presence of ASD diagnosis, and the independent variables included E/I spatial autocorrelation (Moran's I)and sex. We obtained sex-matched ASD and NT populations younger than 48 months using the *MatchIt* library[35]. We specified a 3:1 ratio (four ASD cases for each control) to ensure a sufficient sample size in the sex-matched population. To assess the performance of the model, a receiver operating characteristic (ROC) curve was constructed using the *roc* function from the R *pROC* package[42], where the outcome variable and the predicted probabilities from the model were supplied as the response and predictor, respectively. The area under the ROC curve (AUC) was then calculated to evaluate the discriminative ability of the model.

Competing Interests:

In the last 2 years, BV has received consultant honoraria from Simon-Kucher, Medice, Angelini (Ethos), and Alkermes Pharmaceuticals.

Author contributions:
DM was responsible for the study conceptualization. VFC and DM were responsible for the study design. VFC curated the data and conducted the investigation. DM designed and performed the analyses. The initial draft of the manuscript was prepared by VFC and DM. CD managed the project and patient recruitment. CD, MV, and BS recruited patients. MG, SM, FSR, and CC performed and evaluated the EEGs. BV, AM, FA, and AG provided critical input to improve the study and interpret the findings. All authors reviewed and commented on the manuscript.

Data availability:
The raw EEG and clinical data that support the findings in this study are not openly available due to privacy requirements imposed by our Research Ethics Committee but deidentified data are available from the corresponding author on reasonable request.
Data for the results validation in an external dataset are available from https://github.com/adede1988/SheffieldAutismBiomarkers .

References:

1. Lord, C., *et al.* Autism spectrum disorder. Nat Rev Dis Primers. 16;6(1):5 (2020).
2. Kamp-Becker, I. Autism spectrum disorder in ICD-11—a critical reflection of its possible impact on clinical practice and research. *Mol. Psychiatry* **29**, 633–638 (2024).
3. Jones, W. *et al.* Eye-Tracking–Based Measurement of Social Visual Engagement Compared With Expert Clinical Diagnosis of Autism. *JAMA* **330**, 854 (2023).
4. Rubenstein, J. L. R. & Merzenich, M. M. Model of autism: increased ratio of excitation/inhibition in key neural systems. *Genes Brain Behav.* **2**, 255–267 (2003).
5. Chao, H.-T. *et al.* Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. *Nature* **468**, 263–269 (2010).
6. Lee, E., Lee, J. & Kim, E. Excitation/Inhibition Imbalance in Animal Models of Autism Spectrum Disorders. *Biol. Psychiatry* **81**, 838–847 (2017).
7. Belmonte, M. K. *et al.* Autism and Abnormal Development of Brain Connectivity: Figure 1. *J. Neurosci.* **24**, 9228–9231 (2004).

8. Duffy, F. H. & Als, H. A stable pattern of EEG spectral coherence distinguishes children with autism from neuro-typical controls - a large case control study. *BMC Med.* **10**, 64 (2012).
9. Markicevic, M. *et al.* Cortical Excitation:Inhibition Imbalance Causes Abnormal Brain Network Dynamics as Observed in Neurodevelopmental Disorders. *Cereb. Cortex* **30**, 4922–4937 (2020).
10. Nelson, S. B. & Valakh, V. Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders. *Neuron* **87**, 684–698 (2015).
11. Yizhar, O. *et al.* Neocortical excitation/inhibition balance in information processing and social dysfunction. *Nature* **477**, 171–178 (2011).
12. Antoine, M. W., Langberg, T., Schnepel, P. & Feldman, D. E. Increased Excitation-Inhibition Ratio Stabilizes Synapse and Circuit Excitability in Four Autism Mouse Models. *Neuron* **101**, 648-661.e4 (2019).
13. Severino, L., Kim, J., Nam, M.-H. & McHugh, T. J. From synapses to circuits: What mouse models have taught us about how autism spectrum disorder impacts hippocampal function. *Neurosci. Biobehav. Rev.* **158**, 105559 (2024).
14. Mapelli, L., Soda, T., D'Angelo, E. & Prestori, F. The Cerebellar Involvement in Autism Spectrum Disorders: From the Social Brain to Mouse Models. *Int. J. Mol. Sci.* **23**, 3894 (2022).
15. Trakoshis, S. *et al.* Intrinsic excitation-inhibition imbalance affects medial prefrontal cortex differently in autistic men versus women. *eLife* **9**, e55684 (2020).
16. Horder, J. *et al.* Glutamate and GABA in autism spectrum disorder—a translational magnetic resonance spectroscopy study in man and rodent models. *Transl. Psychiatry* **8**, 106 (2018).
17. Robertson, C. E., Ratai, E.-M. & Kanwisher, N. Reduced GABAergic Action in the Autistic Brain. *Curr. Biol.* **26**, 80–85 (2016).
18. Rideaux, R. Temporal Dynamics of GABA and Glx in the Visual Cortex. *eneuro* **7**, ENEURO.0082-20.2020 (2020).
19. Juarez-Martinez, E. L. *et al.* Qualitative EEG abnormalities signal a shift towards inhibition-dominated brain networks. Results from the EU-AIMS LEAP studies. Preprint at https://doi.org/10.1101/2024.09.19.613847 (2024).
20. Silverman, J. L. *et al.* GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism. *Neuropsychopharmacology* **40**, 2228–2239 (2015).

21. Veenstra-VanderWeele, J. *et al.* Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. *Neuropsychopharmacology* **42**, 1390–1398 (2017).
22. Oberman, L. M. *et al.* Transcranial magnetic stimulation in autism spectrum disorder: Challenges, promise, and roadmap for future research. *Autism Res.* **9**, 184–203 (2016).
23. Frith, U. *Autism: Explaining the Enigma*. (Blackwell Pub, Malden, MA, 2005).
24. Schwartz, S., Kessler, R., Gaughan, T. & Buckley, A. W. Electroencephalogram Coherence Patterns in Autism: An Updated Review. *Pediatr. Neurol.* **67**, 7–22 (2017).
25. Murias, M., Webb, S. J., Greenson, J. & Dawson, G. Resting State Cortical Connectivity Reflected in EEG Coherence in Individuals With Autism. *Biol. Psychiatry* **62**, 270–273 (2007).
26. Peyrache, A. *et al.* Spatiotemporal dynamics of neocortical excitation and inhibition during human sleep. *Proc. Natl. Acad. Sci.* **109**, 1731–1736 (2012).
27. Niethard, N. *et al.* Sleep-Stage-Specific Regulation of Cortical Excitation and Inhibition. *Curr. Biol.* **26**, 2739–2749 (2016).
28. Donoghue, T. *et al.* Parameterizing neural power spectra into periodic and aperiodic components. *Nat. Neurosci.* **23**, 1655–1665 (2020).
29. Brake, N. *et al.* A neurophysiological basis for aperiodic EEG and the background spectral trend. *Nat. Commun.* **15**, 1514 (2024).
30. McKeown, D. J. *et al.* Test-retest reliability of spectral parameterization by 1/ *f* characterization using *SpecParam*. *Cereb. Cortex* **34**, bhad482 (2024).
31. Dell'Isola, G. B. *et al.* Effect of melatonin on sleep quality and EEG features in childhood epilepsy: a possible non-conventional treatment. *Front. Neurol.* **14**, 1243917 (2023).
32. Kim, J. H. *et al.* First-Generation Antihistamines and Seizures in Young Children. *JAMA Netw. Open* **7**, e2429654 (2024).
33. Dede, A. J. O., Xiao, W., Vaci, N., Cohen, M. X. & Milne, E. Exploring EEG resting state differences in autism: sparse findings from a large cohort. *Mol. Autism* **16**, 13 (2025).
34. Wilkinson, C. L. *et al.* Developmental trajectories of EEG aperiodic and periodic components in children 2–44 months of age. *Nat. Commun.* **15**, 5788 (2024).
35. Ho, D., Imai, K., King, G. & Stuart, E. A. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. *J. Stat. Softw.* **42**, 1–28 (2011).
36. Bruining, H. *et al.* Measurement of excitation-inhibition ratio in autism spectrum disorder using critical brain dynamics. *Sci. Rep.* **10**, 9195 (2020).
37. Puts, N. A. J. *et al.* Reduced GABA and altered somatosensory function in children with autism spectrum disorder. *Autism Res.* **10**, 608–619 (2017).

38. Shin Yim, Y. *et al.* Reversing behavioural abnormalities in mice exposed to maternal inflammation. *Nature* **549**, 482–487 (2017).
39. Stoner, R. *et al.* Patches of Disorganization in the Neocortex of Children with Autism. *N. Engl. J. Med.* **370**, 1209–1219 (2014).
40. Masuda, F. *et al.* Motor cortex excitability and inhibitory imbalance in autism spectrum disorder assessed with transcranial magnetic stimulation: a systematic review. *Transl. Psychiatry* **9**, 110 (2019).
41. Bertelsen, N. *et al.* Electrophysiologically-defined excitation-inhibition autism neurosubtypes. Preprint at https://doi.org/10.1101/2023.11.22.23298729 (2023).
42. Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* **12**, 77 (2011).

Table 1. Demographics and clinical characteristics of the ASD and NT samples.

	ASD individuals (N=248)	NT individuals (N=105)	*p-value*
Age, months, mean (SD)	66.11 (41.3)	101.49 (57.22)	$p < 0.01^{\S}$
Males, n (%)	196 (79)	51 (48.6)	$p < 0.01^{\S}$
Comorbidities, n (%)	88 (35)	31 (29.5)	
Intellectual Disability, n (%)	155 (62)	0 (0)*	
Aggressive behaviours, n (%)	93 (37.5)	10 (9.5)	
Hyperactivity, n (%)	69 (27.8)	8 (7.6)	
GI problems, n (%)	47 (19)	5 (4.8)	
Sleep problems, n (%)	67 (27)	12 (11.4)	
Pharmacological therapy, n (%)	34 (13.7)	8 (7.6)	
DSM level of severity		*Reason of admission*	

Level 1, n (%)	31 (12.5)	Loss of consciousness, n (%)	38 (36.2)
Level 2, n (%)	64 (25.8)	Non-epileptic paroxysmal movements, n (%)	28 (26.7)
Level 3, n (%)	58 (23.4)	Headache, n (%)	25 (23.8)
Missing values, n (%)	95 (38.3)	Altered consciousness, n (%)	6 (5.7)
		Vertigo, n (%)	6 (5.7)
		Others, n (%)	2 (1.9)

§ t-test was used to compare age in the two groups. Fisher's exact test was employed for comparing sex differences. Considering the significant group differences, we performed a series of sensitivity analyses to reasonably ensure that the observed results were not driven by differences unrelated to ASD.

**Intellectual disability was not formally assessed in the control group.*

Table 2. Spatial autocorrelation of E/I in sleep and wake EEGs

	E/I spatial autocorrelation across EEG electrodes		
Regressors	*Estimates*	*95% CI*	*p-value*
ASD	-0.51	-0.69 – -0.33	**<0.001**
Age	0.05	-0.04 – 0.14	0.28
Sex (M)	0.12	-0.08 – 0.31	0.23
Random Effects			
ICC	0.25		

ASD EEGs n = 343; NT EEGs n = 197

Table 3. Association between E/I spatial autocorrelation and ASD severity level

	E/I spatial autocorrelation		
Regressors	*Estimates*	*CI*	*p*
ASD DSM-V level	0.05	-0.10 – 0.20	0.516
Age (months)	0.18	0.03 – 0.33	**0.021**
Sex (M)	0.00	-0.38 – 0.38	0.987

EEGs n = 209

Table 4. Spatial autocorrelation of E/I separately analysed in sleep and wake EEGs

	E/I Moran's I across EEG electrodes in wakefulness			E/I Moran's I across EEG electrodes in sleep		
Regressors	*Estimates*	*95% CI*	*p-value*	*Estimates*	*95% CI*	*p-value*
ASD	- 0.36	-0.63 – -0.081	**0.010**	-0.49	-0.75 – -0.23	**<0.001**
Age	-0.04	-0.17– 0.09	0.589	0.12	0.00– 0.23	**0.046**
Sex (M)	0.14	-0.14 – 0.41	0.333	0.04	-0.21– 0.29	0.768

n	234	304

Results of two separates linear regression in wakefulness (left side of the table) and sleep EEGs (right). P-values refers to the results of the estimates of the independent variables for each model separately.

Figure 1. Diagnostic performances of a regression including E/I Moran's I and sex.



ASD n = 211; NT n = 93.

Supplementary Table 1. EEG Data and EEG reported anomalies in ASD vs. NT Groups

EEG	**Sleep (n)**	**Wake (n)**	**Both (n)**	**EEG Anomalies (%)**
ASD	211	133	95	61.7
NT	94	104	94	25.2

Supplementary Table 2. Average E/I across electrodes in both sleep and wakefulness

Average E/I			
Regressors	**Estimates**	**CI**	**p-value**
ASD	-0.08	-0.25 – 0.09	0.348
Age	-0.09	-0.00 – 0.00	**0.028**
Sex	0.02	-0.06 – 0.10	0.635
Random Effects			
ICC	0.47		

ASD EEGs n = 343; NT EEGs n = 197

Supplementary Table 2b. Average E/I across electrodes in sleep EEGs

Average E/I (sleep)

Regressors	Estimates	CI	p-value
ASD	0.19	-0.08 – 0.45	0.168
Age	-0.15	-0.26 – 0.03	**0.016**
Sex	0.01	-0.11 – 0.12	0.900

ASD EEGs n = 213; NT EEGs n = 94

Supplementary Table 2c. Average E/I across electrodes in wakefulness EEGs

Average E/I (wakefulness)

Regressors	Estimates	95% CI	p-value
ASD	-0.33	-0.62 – -0.05	**0.020**
Age	-0.11	-0.14 – 0.13	0.986
Sex	-0.03	-0.17 – 0.10	0,654

ASD EEGs n = 130; NT EEGs n = 105

Supplementary Table 3. Beta power spatial autocorrelation across EEG electrodes in both sleep and wakefulness.

Beta Power spatial autocorrelation			
Regressors	**Estimates**	**95% CI**	**p-value**
ASD	-0.44	-0.63 – -0.24	**<0.001**
Age	0.03	-0.08 – 0.13	0.591
Sex	0.06	-0.15 – 0.27	0.558
Random Effects			
ICC	0.29		

ASD EEGs n = 197; NT EEGs n = 197

Supplementary Table 4. E/I spatial autocorrelation across EEG electrodes in both sleep and wakefulness in age-matched samples

E/I spatial autocorrelation			
Regressors	**Estimates**	**95% CI**	**p-value**
ASD	-0.40	-0.63 – -0.17	**0.001**
Age	0.08	-0.03 – 0.19	0.148
Sex	0.03	-0.19 – 0.26	0.785
Random Effects			
ICC	0.70		

ASD EEGs n = 343; NT EEGs n = 197

Supplementary Table 5a. E/I spatial autocorrelation excluding patients who received dimetindene maleate in both sleep and wakefulness EEG.

E/I spatial autocorrelation

Regressors	Estimates	95% CI	p-value
ASD	-0.54	-0.74 – -0.34	**<0.001**
Age	0.07	-0.04 – 0.17	0.205
Sex	0.15	-0.06 – 0.36	0.151
Random Effects			
ICC	0.31		

ASD EEGs n = 230; NT EEGs n = 197

Supplementary Table 5b. E/I spatial autocorrelation excluding patients who received melatonin as a sleep aid for their sleep EEG.

E/I spatial autocorrelation

Regressors	Estimates	95% CI	p-value
ASD	-0.34	-0.63 – -0.04	0.025
Age	0.15	0.00 – 0.30	0.047
Sex	0.19	-0.11 – 0.04	0.213
Random Effects			
ICC	0.50		

ASD EEGs n = 132; NT EEGs n = 111

Supplementary Table 6. E/I spatial autocorrelation excluding ASD patients with epileptiform or slow wave anomalies.

E/I spatial autocorrelation

Regressors	Estimates	95% CI	p-value
ASD	-0.45	-0.69 – -0.21	**<0.001**
Age	0.14	-0.01 – 0.27	**0.035**
Sex	0.38	0.11 – 0.64	**0.006**
Random Effects			
ICC	0.36		

ASD EEGs n = 127; NT EEGs n = 147

Supplementary Table 7. E/I spatial autocorrelation excluding ASD patients with intellectual disability/global developmental delay.

E/I spatial autocorrelation

Regressors	Estimates	95% CI	p-value
ASD	-0.42	0.65 – -0.18	**0.001**
Age	0.03	-0.09 – 0.15	0.614
Sex	0.22	-0.03 – 0.47	0.090
Random Effects			
ICC	0.35		

ASD EEGs n = 125; NT EEGs n = 197

Supplementary Table 8. E/I spatial autocorrelation in the dataset used in Dede et al., 2025.

E/I spatial autocorrelation

Regressors	Estimates	95% CI	p

ASD	-0.22	-0.33 – -0.02	**0.033**
Age	0.01	-0.09 – 0.11	0.841
Sex	0.09	-0.12 – 0. 30	0.403

Supplementary Table 9a. E/I spatial autocorrelation in age-matched populations in wakefulness.

Regressors	**Estimates**	**CI**	**p**
ASD	-0.30	-0.58 – -0.02	**0.036**
Age	0.07	-0.20 – 0.07	0.328
Sex	0.09	-0.19 – 0.37	0.534

ASD EEGs n = 104; NT EEGs n = 104

Supplementary Table 9b. E/I spatial autocorrelation in age-matched populations in sleep.

Regressors	Estimates	95% CI	p
ASD	-0.46	-0.74 – -0.17	0.002
Age	0.12	-0.02 – 0.27	0.098
Sex	0.00	-0.28 – 0.29	0.971

ASD EEGs n = 93; NT EEGs n = 93

Supplementary Table 10a. Mass Univariate Test Results for Wakefulness EEGs

Electrode	t-test	p-value
Fp1	-1.62	0.11
Fp2	-1.32	0.19
F7	-3.16	**0.001**
F3	-1.65	0.10
Fz	-1.03	0.31
F4	-2.17	**0.03**
F8	-2.72	**0.007**
T3	-1.07	0.29
C3	-0.74	0.46
Cz	-0.87	0.38

C4	-0.87	0.38
T4	-1.83	0.07
T5	-2.19	**0.03**
P3	-1.89	0.05
Pz	-1.85	0.06
P4	-2.60	**0.009**
T6	-3.07	**0.002**
O1	-2.27	**0.02**
O2	-1.76	0.08

Supplementary Table 10b. Mass Univariate Test Results for Sleep EEGs

Electrode	t-test	p-value
Fp1	2.44	**0.01**
Fp2	4.04	**<0.001**
F7	-0.37	0.71
F3	0.19	0.85
Fz	1.62	0.11
F4	-0.03	0.97
F8	0.12	0.91

T3	3.29	**0.001**
C3	2.91	**0.005**
Cz	1.58	0.11
C4	2.84	**0.004**
T4	3.10	**0.002**
T5	-0.76	0.44
P3	-0.70	0.48
Pz	1.29	0.19
P4	-0.46	0.64
T6	-0.43	0.66
O1	1.86	0.06
O2	2.25	**0.02**


ROC Curve - All individuals
Sensitivity
1 - Specificity
0.00
0.25
0.50
0.75
1.00
AUC = 0.725